Guidance for Management of Survivors of Ebola Disease in U.S. Healthcare Settings

This guidance may be updated based on new data if indicated.

All available data on Ebola disease comes from people infected with Ebola virus (species Zaire ebolavirus). However, we expect this data to be applicable to all ebolaviruses known to cause disease in people (Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus).

In the wake of the largest outbreak of Ebola disease in West Africa from 2014 to 2016, and with the improvements seen in supportive care delivery in field settings, there are now many survivors of Ebola disease, including those experiencing sequelae of the disease. Of the eleven patients with Ebola disease who were managed in U.S. healthcare facilities during 2014-2015, nine survived. It is possible that some Ebola disease survivors could seek medical care in the U.S. The purpose of this document is to provide:

  • Information about sequelae and ebolavirus persistence in Ebola disease survivors.
  • Infection prevention and control recommendations for U.S. healthcare providers when evaluating a patient who is a survivor of Ebola disease.

Data on the pathogenesis of sequelae in Ebola disease survivors and complications related to viral persistence are very limited; few data are available from animal models.

Survivors can experience complications after surviving acute Ebola disease. The timing of onset, severity, and duration of complications among Ebola disease survivors are variable. Reported complications among survivors include non-specific fatigue, joint pain, muscle aches, headaches, suppurative parotitis, pericarditis, orchitis, sexual dysfunction, hair loss, vision loss (including uveitis and permanent blindness), hearing loss, tinnitus, paresthesia or dysesthesia, memory loss, insomnia, depression, anxiety, and post-traumatic stress disorder1-10).

Ebola virus (EBOV; species Zaire ebolavirus) can persist for several months after acute infection in organs that are considered “immunologically privileged sites” – sites that are shielded from the survivor’s immune system (e.g., testes, eye, central nervous system). EBOV was isolated from a semen specimen collected 82 days after acute onset of Ebola disease from a male survivor13. Molecular evidence suggested sexual transmission of EBOV from an asymptomatic male survivor to a female partner 179 days after the survivor’s disease onset14. The potential for residual infectious risk from EBOV persistence is further highlighted by recovery of infectious EBOV in cerebrospinal fluid collected at 282 days after onset of Ebola disease from a survivor who experienced late onset of meningoencephalitis signs and symptoms1, and isolation of EBOV from an intraocular fluid specimen of an eye affected by panuveitis collected at 14 weeks after onset of Ebola disease16. It is unknown whether EBOV can persist in synovial fluid with or without accompanying arthritis. Table 1 summarizes data available to date on detection of EBOV RNA by reverse transcription-polymerase chain reaction (RT-PCR) or recovery of viable EBOV in viral culture from different clinical specimens.

Patients who recover from acute Ebola disease and later become ill with neurologic or ocular symptoms might have persistent ebolavirus replication in the CNS or eye respectively. The risk of infectivity from patients with persistent infection in immune privileged sites is unknown but appears to be low and is likely to decrease over time. Appropriate infection control practices, such as those recommended for evaluating patients with suspect Ebola disease, should be adhered to until testing is negative. This includes any time there could be potential contact with spinal fluid, semen, or ocular contents (e.g., lumbar puncture, spinal anesthesia, prostate or testicular surgery, and intraocular procedures).

Ebola disease survivors who have any new or recurrent ocular or neurologic symptoms should seek care for complications associated with potential virus persistence. Survivors with fever should be assessed for both common community-acquired infections (e.g., malaria, influenza, common cold, typhoid fever, gastroenteritis, etc.), as well as possible complications related to virus persistence.

Table 1. Ebola virus persistence data in different clinical specimens to date (December 2022).
Anatomic compartment Body fluid(s) or tissue(s) Longest time from illness onset that Ebola virus RNA or infectious virus was detected in clinical specimens after illness onset, days [reference]
Ebola virus RNA detected by RT-PCR or viral antigens detected by other assays Infectious Ebola virus recovered
Eye Aqueous humor 14 weeks after illness onset by RT-PCR16 14 weeks after illness onset by virus isolation16
Conjunctival swab 22 days after illness onset by RT-PCR13


No published data
Central nervous system Cerebrospinal fluid 10 months after illness onset by RT-PCR1 No published data
Testes Seminal fluid 40 months after illness onset by RT-PCR15 82 days after illness onset by virus isolation13
Breast Breast milk 16 months (500 days) after discharge from treatment center by RT-PCR21 15 days after illness onset by virus isolation11
Urinary tract Urine 64 days after illness onset by RT-PCR17 26 days by virus isolation18
Genito-urinary tract Vagina 36 days after illness onset by RT-PCR12 No published data
Joints Synovial fluid No animal model data, very limited Ebola Disease patient data, unknown
Gastrointestinal tract Rectal swab 29 days after illness onset by RT-PCR13 No published data
Saliva 8 days after illness onset by RT-PCR11 4-8 days after illness onset by virus culture11
Vomit No published data No published data
Feces 12 days after illness onset by RT-PCR11 No published data
Lower respiratory tract Viral antigens detected in alveolar macrophages; viral inclusions observed in intra-alveolar macrophages, with free virus particles within alveolar spaces in fatal cases20 No published data
Other Sweat (underarm) 44 days after illness onset by RT-PCR17  No published data
Skin (on the hand) 6 days after illness onset by RT-PCR11 No published data
Amniotic fluid >=32 days after disappearance of virus from maternal blood by RT-PCR19 No published data
Placenta >32 days after disappearance of virus from maternal blood by RT-PCR19 No published data
Cord blood >32 days after disappearance of virus from maternal blood by RT-PCR19 No published data


Nasal blood 10 days after illness onset by RT-PCR11 No published data

Guidance for Clinical Assessment of Ebola Disease Survivors

Healthcare personnel should not withhold any care from survivors of Ebola disease. All patient care delivery (i.e., in patients both known and not known to be Ebola disease survivors) should be performed using Standard Precautions. These constitute the minimum set of infection control practices used to ensure that healthcare personnel do not contract infections from patients, whether or not they are known to be infectious, and that personnel do not spread infectious material to other patients during routine medical care.

For patients who fully recover from Ebola disease and subsequently seek medical care (Ebola disease  survivors who recover and are discharged after their acute disease clinical course):

  • Standard Precautions and correct waste management should remain in effect while appropriate clinical evaluation and care is performed. Based on observations during the 2014 West African Ebola disease outbreak and previous outbreaks, there is no current evidence that the routine clinical care of Ebola disease survivors poses any special risk to healthcare personnel when this care involves contact with intact skin, sweat, tears, conjunctivae, saliva, or cerumen.
  • There is no evidence that people who become pregnant after they recover from Ebola disease pose special risk to healthcare providers. They should receive routine prenatal care with Standard Precautions* and correct waste management used during labor and delivery with attention paid to splash prevention.
  • In the absence of neurologic symptoms, regional anesthesia should not pose a risk to hospital staff. (For those pregnant survivors with neurologic symptoms who require spinal anesthesia during delivery, see below).
  • Available evidence indicates that people who have fully recovered from Ebola disease and are not febrile, do not manifest ebolavirus viremia and do not pose a risk of exposure through phlebotomy.
  • Specific procedures that create the opportunity for contact with body fluids from immunologically protected sites merit special consideration. Although data are limited, there is recognized potential for virus persistence in certain body fluids and tissues as summarized in Table 1. Examples include: obtaining and handling CSF from an Ebola disease survivor with CNS symptoms; performing an invasive ophthalmologic procedure on an affected eye in a patient with ocular disease such as uveitis or cataract; and procedures involving exposure to semen, such as infertility evaluations, or performing invasive procedures on the testes, prostate gland, or seminal vesicles. It is unknown whether ebolavirus may persist in synovial fluid of survivors. For these, and any other care activities that might involve contact with such body fluids (including lumbar puncture, spinal anesthesia), healthcare facilities and clinicians should:
    • Arrange expert consultation in advance or on an urgent basis as needed (i.e., through the state health department and/or CDC)
    • Assess capabilities of the facility and ability to correctly implement and maintain infection control, including contact precautions, environmental hygiene, and infectious waste management as needed (including in consultation with CDC in advance or on an urgent basis)
    • Assess the readiness, training and competence of all staff potentially involved in care, and their willingness to remain part of the care team knowing the possible risk of virus persistence (this should include any diagnostic laboratory and imaging personnel, environmental services staff, and care providers)
    • Determine appropriate personal protective equipment (PPE) based on a risk assessment of potential exposure during the procedure(s) and related care and ensure training on its use. Based on these assessments, and in consultation with public health authorities, safe care delivery can be arranged either at the original facility or, at the discretion of local and State public health authorities and in consultation with CDC, at an appropriate referral facility.

*Healthcare personnel should use precautions when there is potential contact with blood, body fluids or broken skin, and any potential for splashing or exposure to a soiled surface during care, for which non-sterile gloves, disposable gowns, and face protection to prevent mucosal exposure should be used based on the expected risk.

  1. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RSN, MacConnachie A, Mahungu T, Martin D, Marshall N, Mephan S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilikie GS, Zambon M, Gopal R, Thomson EC. Late Ebola virus relapse causing meningoencephalitis: a case report. The Lancet. 10043 (2016): 498-503.
  2. Qureshi AI, Chughtai M, Loua TO, Pe Kolie J, Camara HF, Ishfaq MF, N’Dour CT, Beavogui K. Study of Ebola Virus Disease Survivors in Guinea. Clin Infect Dis. 2015 Oct 1;61(7):1035-42.
  3. Nanyonga M, Saidu J, Ramsay A, Shindo N, Bausch DG. Sequelae of Ebola Virus Disease, Kenema District, Sierra Leone. Clin Infect Dis. 2016 Jan 1;62(1):125-6.
  4. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post EVD signs and symptoms in U.S. survivors. N Engl J Med. 2015;373:2484-6.
  5. Mohammed A, Sheikh TL, Gidado S, Poggensee G, Nguku P, Olayinka A, Ohuabunwo C, Waziri N, Shuaib F, Adeyemi J, Uzoma O, Ahmed A, Doherty F, Nyanti SB, Nzuki CK, Nasidi A, Oyemakinde A, Oguntimehin O, Abdus-Salam IA, Obiako RO. An evaluation of psychological distress and social support of survivors and contacts of Ebola virus disease infection and their relatives in Lagos, Nigeria: a cross sectional study–2014. BMC Public Health. 2015 Aug 27;15:824.
  6. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015 Aug;15(8):905-12.
  7. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, Bwaka MA, De Roo A, Colebunders R. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999 Feb;179 Suppl 1:S13-4.
  8. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, Van den Enden E, Van den Enden E. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999 Feb;179 Suppl 1:S1-7.
  9. Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT, Madoff LC, Droms RJ, Hinkle DM,  Asdourian GK, Finberg RW, Stroher U, Uyeki TM, Cerón OM. Uveitis and systemic inflammatory markers in convalescent phase of Ebola virus disease. Emerg Infect Dis. 2016 Feb [date cited].
  10. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, Brooks T, Conteh S, Crozier I, Fowler RA, Kamara AP, Kang C, Mahadevan S, Mansaray Y, Marcell L, McKay G, O’Dempsey T, Parris V, Pinto R, Rangel A, Salam AP, Shantha J, Wolfman V, Yeh S, Chan AK, Mishra S. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2015 Dec 22. pii: S1473-3099(15)00489-2. doi: 10.1016/S1473-3099(15)00489-2. [Epub ahead of print]
  11. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007 Nov 15;196 Suppl 2:S142-7.
  12. Lui, W, et al. Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease: Sierra Leone Ebola Virus Persistence Study Open Forum Infect Dis. 2019 Feb 26;6(3)
  13. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, Williams AJ, Rowe AK, Bertolli J, Khan AS, Ksiazek TG, Peters CJ, Nichol ST. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999 Feb;179 Suppl 1:S170-6.
  14. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Ströher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty P, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G. Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med. 2015 Dec 17;373(25):2448-54.
  15. PREVAIL III Study group. A longitudinal study of ebola sequelae in Liberia. N Engl J Med. 2019;380:924-34. DOI: 10.1056/NEJMoa1805435
  16. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med. 2015 Jun 18;372(25):2423-7.
  17. Howlett P, Brown C, Helderman T, Brooks T, Lisk D, Deen G, Solbrig M, Lado M. Ebola Virus Disease Complicated by Late-Onset Encephalitis and Polyarthritis, Sierra Leone. Emerg Infect Dis. 2016 Jan;22(1):150-152.
  18. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, Sow A, Renné T, Günther S, Lohse AW, Addo MM. A case of severe Ebola virus infection complicated by gram-negative septicemia. New england journal of medicine. 2014 Dec 18;371(25):2394-401.
  19. Caluwaerts S, Fautsch T, Lagrou D, Moreau M, Modet Camara A, Günther S, Di Caro A, Borremans B, Raymond Koundouno F, Akoi Bore J, Logue CH. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clinical Infectious Diseases. 2015 Dec 17;62(7):903-5.
  20. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015 Jan;235(2):153-74.
  21. Keita AK, Vidal N, Toure A, Diallo MSK, Magassouba N, Baize S, Mateo M, Raoul H, Mely S, Subtil A 40-month follow-up of Ebola virus disease survivors in Guinea (PostEbogui) reveals long-term detection of Ebola viral ribonucleic acid in semen and breast milk. Open Forum Infect Dis. 2019 Nov 8;6(12):ofz482. doi:10. 1093/ofid/ofz482. eCollection 2019 Dec.